Triple-negative breast cancer (TNBC) is widely recognized as the most aggressive form of breast cancer, occurring more frequently in younger patients and characterized by high heterogeneity, early distant metastases and poor prognosis. Multiple treatment options have failed to achieve the expected therapeutic effects due to the lack of clear molecular targets. Based on genomics, transcriptomics and metabolomics, the multi-omics analysis further clarifies TNBC subtyping, which provides a greater understanding of tumour heterogeneity and targeted therapy sensitivity. For instance, the luminal androgen receptor subtype (LAR) exhibits responsiveness to anti-AR therapy, and the basal-like immune-suppressed subtype (BLIS) tends to benefit from poly (ADP-ribose) polymerase inhibitors (PARPis) and anti-angiogenic therapy. The efficacy of multi-dimensional combination therapy holds immense importance in guiding personalized and precision medicine for TNBC. This review offers a systematic overview of recent FuDan TNBC molecular subtyping and its role in the instruction of clinical precision therapy.

中文翻译：

---

三阴性乳腺癌的分子分型与精准医疗——基于复旦TNBC分型

三阴性乳腺癌（TNBC）被广泛认为是最具侵袭性的乳腺癌形式，在年轻患者中更常见，其特点是异质性高、早期远处转移和预后不良。由于缺乏明确的分子靶点，多种治疗方案未能达到预期的治疗效果。基于基因组学、转录组学和代谢组学的多组学分析进一步阐明了TNBC亚型，从而更好地了解肿瘤异质性和靶向治疗敏感性。例如，管腔雄激素受体亚型（LAR）表现出对抗 AR 治疗的反应性，而基础样免疫抑制亚型（BLIS）往往受益于聚（ADP-核糖）聚合酶抑制剂（PARPis）和抗血管生成药物。治疗。多维联合治疗的疗效对于指导TNBC的个体化、精准医疗具有重要意义。本综述系统地概述了近期复旦大学 TNBC 分子分型及其在临床精准治疗指导中的作用。